Medical devices, healthcare technology and the business of care
PMA approval · P250026

Atellica IM free PSA II (fPSAII)

Siemens Healthcare Diagnostics, Inc. · Decision date May 11, 2026

FDA DECISIONP250026

What did the FDA approve?

FDA records P250026 as an original PMA application. The recorded decision is approval, dated May 11, 2026.

FDA approval order statement

Approval for the Atellica IM free PSA II (fPSAII):The Atellica IM free PSA II (fPSAII) assay is for in vitro diagnostic use in the quantitative measurement of free prostate-specific antigen (fPSA) in human serum and plasma (lithium heparin and EDTA) using the Atellica IM Analyzer. The Atellica IM fPSAII assay is intended to be used in conjunction with the Atellica IM total PSA II (tPSAII) assay in men aged 50 years and older with total prostate-specific antigen (PSA) values between 4 ng/mL (µg/L) and 10 ng/mL (µg/L) and a digital rectal examination (DRE) non-suspicious for cancer to determine the percent free PSA value. The percent free PSA value can be used as an aid in discriminating between prostate cancer and benign prostatic disease. A prostate biopsy is required for the diagnosis of prostate cancer.
Regulatory pathway
Original PMA
Clinical specialty
Immunology
Decision date
May 11, 2026

FDA source record

Regulatory record facts

Identifier
P250026
Regulatory pathway
Premarket approval application
Product code
MTG
Decision code
APPR
Decision date
May 11, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Test, prostate specific antigen, free, (noncomplexed) to distinguish prostate cancer from benign conditions.

Product code
MTG
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P250026 received

    Application receipt date recorded by FDA.

  2. P250026 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P250026. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code MTG

Product / regulatory recordCompanyPathwayDecision dateSource
Siemens Medical Solutions Diagnostics LimitedPMA supplementSep 22, 2026FDA
Siemens Medical Solutions Diagnostics LimitedPMA supplementAug 20, 2026FDA
Siemens Medical Solutions Diagnostics LimitedPMA supplementJul 27, 2026FDA
Siemens Medical Solutions Diagnostics LimitedPMA supplementApr 21, 2026FDA
ABBOTT LABORATORIESPMA supplementFeb 12, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Siemens Healthcare Diagnostics, Inc.

Headquarters
Not reported
FDA applicant address
511 Benedict Ave., Tarrytown, NY, 10591

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records